Verthermia Heatt to Treat
Verthermia (Verthermia Acquisitions Inc.) is a private medical technology company that delivers HEATT® whole-body hyperthermia therapy—circulating a patient's externally heated blood at 42°C for 120 minutes—to advanced-stage cancer patients and chronic Lyme disease patients at a single facility at First Baptist Medical Center in Dallas, TX.
- Company typePrivate
- Founded2012
- HeadquartersDallas, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Verthermia Heatt to Treat does
Verthermia (legal entity: Verthermia Acquisitions Inc., a Nevada-incorporated private company founded in 2012, headquartered in Henderson NV with treatment operations in Dallas, TX) has developed and commercialized HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy), a whole-body hyperthermia procedure that targets advanced-stage cancer and chronic Lyme disease. The HEATT procedure assembles FDA-approved heart-lung machine and dialysis components—including the patent-pending CoreHFC™ device—into a proprietary external circuit that withdraws a patient's blood, heats it externally, and returns it to the body via the right heart, raising core body temperature to 42°C (107.6°F) for 120 minutes while conducting charcoal-filtration dialysis to normalize fluids, electrolytes, and pH. The system is protected by four issued US patents (with two pending US applications and one PCT international application), and Verthermia has completed FDA Phase 1 clinical trials in ovarian and lung cancer, with the ovarian trial reporting 21.2-month median overall survival versus 8.9 months expected and 80% of patients exceeding predicted survival.
The company delivers HEATT as a treatment service exclusively at First Baptist Medical Center in Dallas, with typical patient hospital stays of 3–4 days and per-cycle pricing arranged via consultation rather than published rates. Its go-to-market is sales-led and inside-sales driven—patient acquisition runs through HubSpot scheduling, dedicated phone lines, medical provider referrals, content marketing (blog and YouTube testimonials), and direct outreach to advanced cancer patients who have exhausted conventional surgery, radiation, chemotherapy, and immunotherapy options. Primary customer segments are advanced/Stage IV cancer patients (with indication-specific pages for ovarian, breast, colon, and lung cancer), with secondary applications in pancreatic cancer and Lyme disease treated with antibiotic adjunct therapy. Verthermia is privately held, operates with 1–10 employees, has raised approximately $2.03 million in disclosed outside funding across two rounds (2013 and 2021), and is led by CEO Mitchel K. May alongside a credentialed clinical leadership team including a cardiothoracic surgeon/CMO, a perfusionist/CSO, and a Cornell-trained nephrologist/CCO, supported by an advisory board drawn from Memorial Sloan Kettering, Cleveland Clinic, Mount Sinai, Harvard/Massachusetts General/Dana-Farber, and Allegheny Health Network.
Verthermia Heatt to Treat firmographics
Firmographics- Name
- Verthermia Heatt to Treat
- Legal name
- Verthermia Acquisitions INC
- Website
- https://verthermia.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Verthermia (Verthermia Acquisitions Inc.) is a private medical technology company that delivers HEATT® whole-body hyperthermia therapy—circulating a patient's externally heated blood at 42°C for 120 minutes—to advanced-stage cancer patients and chronic Lyme disease patients at a single facility at First Baptist Medical Center in Dallas, TX.
- Ownership category
- akta.pro rank
Verthermia Heatt to Treat industry classification
Industry- Product category
- Whole-Body Hyperthermia Treatment
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
- akta.pro primary industry
- Hot/Cold Therapy Services (Cryotherapy/Ice Baths) (HSALAFAH)
- akta.pro secondary industry
- Hot/Cold Contrast Therapy (Hot Tubs, Plunge Pools & Hydrotherapy) (HSADAKAD)
Keywords
Where Verthermia Heatt to Treat is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Verthermia Heatt to Treat business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- HEATT Treatment Services: Medical treatment services providing whole-body hyperthermia therapy for cancer patients. Treatment involves multiple day hospital stays and is performed at First Baptist Medical Center. Revenue generated through per-treatment cycle billing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based treatment pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Verthermia Heatt to Treat product offering
Product offeringCore offering
Verthermia provides HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy), a whole-body hyperthermia procedure that circulates a patient's blood through an external FDA-approved circuit, heating it to 42°C (107.6°F) for two hours to target cancer cells. The procedure is performed at First Baptist Medical Center in Dallas, Texas and is also applied as a treatment protocol for Lyme disease using elevated body temperature combined with antibiotic therapy.
Product overview
Verthermia offers HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy) as its core treatment product, a whole-body hyperthermia procedure that heats patient blood to 42°C using the proprietary CoreHFC™ device. The treatment is indicated for multiple cancer types including ovarian, breast, colon, and lung cancer, as well as Lyme disease. HEATT therapy works by circulating heated blood through an external FDA-approved circuit while normalizing fluids, electrolytes, and pH balance through dialysis, directly targeting cancer cells that cannot tolerate elevated temperatures. The company also provides disease-specific treatment protocols and has completed FDA Phase 1 clinical trials demonstrating safety and efficacy.
Differentiator
Problem solved
Functional benefit
Products and services
- HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy)
Quantifiable outcome
- Median survival increased from 8.9 months expected to 21.2 months actual for ovarian cancer patients (80% of trial patients exceeded predicted survival)
- +3 more outcomes
Companies that use Verthermia Heatt to Treat
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Verthermia Heatt to Treat technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Verthermia Heatt to Treat partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- First Baptist Medical CentercoreTreatment facility where all HEATT procedures are performed. Located in Dallas, Texas. The operating room at First Baptist Medical Center serves as the primary treatment site, with recovery room care included as part of the HEATT treatment process. The facility provides a state-of-the-art environment for patient care.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Verthermia Heatt to Treat competitors and assessment
Company assessmentDirect peers
- Pyrexar Medical: Hyperthermia medical device manufacturer (formerly BSD Medical) that produces systems for treating cancer with localized and regional hyperthermia. Directly competes with Verthermia in the oncology hyperthermia category with overlapping technology approach.
- Oncotherm: German manufacturer of regional deep hyperthermia devices used as an adjunct to chemo/radiation in oncology. Competes with Verthermia in the cancer hyperthermia modality, although Oncotherm focuses on regional rather than whole-body heating.
- Celsius42: German developer of whole-body hyperthermia systems for oncology and other indications. The most direct technical comparable to HEATT given its whole-body heating approach for cancer.
- Dr. Sennewald Medizintechnik GmbH: German medical device company specializing in hyperthermia systems for cancer treatment. Operates in the same oncology hyperthermia space as Verthermia with comparable clinical positioning.
Emerging players
- Hippocrates Health Institute: Alternative wellness and chronic-disease clinic offering whole-body hyperthermia among other modalities. Comparable as a niche operator delivering hyperthermia-based protocols to self-directed patients.
- Hope4Cancer: Alternative cancer treatment center that incorporates whole-body hyperthermia into its protocols. Comparable as a competing destination clinic for advanced-stage patients seeking non-standard therapies.
- Burzynski Clinic: Long-running alternative oncology clinic offering non-mainstream treatments to late-stage cancer patients. Comparable as a destination provider targeting the same exhausted-treatment patient segment that Verthermia addresses.
Broad incumbents
- City of Hope: One of the largest US comprehensive cancer centers (absorbing CTCA's clinical operations). Relevant as the dominant mainstream oncology provider against which Verthermia's niche last-resort offering must compete for advanced-stage patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Verthermia Heatt to Treat social profiles
Digital presenceVerthermia Heatt to Treat financial estimates
Financial estimateRevenue estimate
Valuation estimate
Verthermia Heatt to Treat leadership team
Management profileNumber of profiles
Profiles1 record
Verthermia Heatt to Treat funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Verthermia Heatt to Treat M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Verthermia Heatt to Treat
What does Verthermia Heatt to Treat do?
Verthermia provides HEATT® (Hyperthermic Extracorporeal Applied Tumor Therapy), a whole-body hyperthermia procedure that circulates a patient's blood through an external FDA-approved circuit, heating it to 42°C (107.6°F) for two hours to target cancer cells. The procedure is performed at First Baptist Medical Center in Dallas, Texas and is also applied as a treatment protocol for Lyme disease using elevated body temperature combined with antibiotic therapy.
Is Verthermia Heatt to Treat a public or private company?
Verthermia Heatt to Treat is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Verthermia Heatt to Treat founded?
Verthermia Heatt to Treat was founded in 2012. It employs 1 to 10 people.
Where is Verthermia Heatt to Treat based?
Verthermia Heatt to Treat is headquartered in Dallas, United States, in the North America region.
How does Verthermia Heatt to Treat make money?
One revenue line is on record: HEATT Treatment Services.
Who are Verthermia Heatt to Treat's main competitors?
Direct peers on record are Pyrexar Medical, Oncotherm, Celsius42 and Dr. Sennewald Medizintechnik GmbH. Emerging players are Hippocrates Health Institute, Hope4Cancer and Burzynski Clinic. City of Hope is listed as a broad incumbent.
Does Verthermia Heatt to Treat have an API?
No public API is recorded for Verthermia Heatt to Treat.
What industry is Verthermia Heatt to Treat in?
Verthermia Heatt to Treat's product category is Whole-Body Hyperthermia Treatment. Its primary akta.pro industry code is HSALAFAH, Hot/Cold Therapy Services (Cryotherapy/Ice Baths), with a secondary code of HSADAKAD, Hot/Cold Contrast Therapy (Hot Tubs, Plunge Pools & Hydrotherapy). Its SIC code is 3845.